Product Description
a CD19 CAR T-cell therapy for the treatment of patients with relapsed/refractory large B cell lymphoma (r/r LBCL). (Sourced from: http://neoimmunetech.com/news/page01_view.html?number=55)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Netherlands, Norway, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Composite Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Inflammation|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Lymphoma
Phase 2: Leukemia|Mantle-Cell Lymphoma
Phase 1: Primary Central Nervous System Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LEDA | P3 |
Recruiting |
Follicular Lymphoma |
2028-07-24 |
41% |
| CASSIOPEIA | P2 |
Recruiting |
Lymphoma, B-Cell|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia |
2027-10-19 |
57% |
| BELINDA | P3 |
Active, not recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Composite Lymphoma |
2027-09-29 |
|
| 2015-003736-13 | P2 |
Active, not recruiting |
Leukemia|Lymphoma, B-Cell |
2027-09-04 |